Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes.
anticancer
clinical pipeline
drug discovery
marine drugs
marine natural products
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
04 Dec 2020
04 Dec 2020
Historique:
received:
16
11
2020
revised:
30
11
2020
accepted:
02
12
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
8
9
2021
Statut:
epublish
Résumé
The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve different pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year. Marine-based pharmaceuticals have started to impact modern pharmacology and different anti-cancer drugs derived from marine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use.
Identifiants
pubmed: 33291602
pii: md18120619
doi: 10.3390/md18120619
pmc: PMC7761941
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Biological Products
0
Marine Toxins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Cooperation in Science and Technology
ID : CA18238
Organisme : Applied Molecular Biosciences Unit-UCIBIO, financed by national funds from FCT/MCTES.
ID : UID/Multi/04378/2019)
Organisme : FCT/MCTES
ID : IF/00700/2014
Organisme : Slovenian Research Agency research core funding
ID : P1-0245
Organisme : TÜBİTAK
ID : 216Z167
Organisme : Ministerio de Ciencia e Innovación
ID : RTA 2015-00010-C03-02
Organisme : Agustin de Betancourt Programme (Cabildo de Tenerife, TFinnova Programme supported by MEDI and FDCAN funds)
ID : -
Organisme : MetaboCell project of Canceropôle Provence-Alpes-Côte d'Azur and the Provence-Alpes-Côte d'Azur Region
ID : -
Organisme : Marine Research Programme by the Irish Government
ID : PBA/MB/16/01 and PDOC/19/02/01
Références
J Nat Prod. 1999 Jul;62(7):959-62
pubmed: 10425116
Cancer Res. 1978 Jun;38(6):1730-3
pubmed: 274175
Molecules. 2020 Oct 16;25(20):
pubmed: 33081383
Pharmacol Ther. 2020 Jul;211:107552
pubmed: 32305312
Anticancer Drug Des. 2000 Feb;15(1):17-28
pubmed: 10888033
Blood. 2014 May 15;123(20):3128-38
pubmed: 24569262
Br J Cancer. 2012 Apr 10;106(8):1379-85
pubmed: 22491421
Cancer Lett. 1996 Apr 19;102(1-2):31-7
pubmed: 8603376
Chem Biol. 2004 Apr;11(4):487-98
pubmed: 15123243
Appl Environ Microbiol. 2006 Dec;72(12):7941-4
pubmed: 16997977
Clin Cancer Res. 2001 Feb;7(2):231-42
pubmed: 11234874
J Clin Oncol. 1999 Oct;17(10):3110-6
pubmed: 10506606
Biochem Pharmacol. 2009 Jul 15;78(2):162-70
pubmed: 19427997
J Med Chem. 1996 Jul 5;39(14):2819-34
pubmed: 8709112
Cancer Res. 2010 Mar 15;70(6):2235-44
pubmed: 20215499
Invest New Drugs. 2013 Jun;31(3):623-30
pubmed: 22688291
Curr Med Chem. 2012;19(16):2652-64
pubmed: 22506770
Cancer. 1967 May;20(5):809-16
pubmed: 6071587
Clin Cancer Res. 2015 Mar 15;21(6):1373-82
pubmed: 25609059
Am J Clin Oncol. 2002 Oct;25(5):451-3
pubmed: 12393982
Cancer Res. 1980 Oct;40(10):3610-5
pubmed: 6254636
J Nat Prod. 2016 Mar 25;79(3):629-61
pubmed: 26852623
Biochemistry. 2010 Feb 16;49(6):1331-7
pubmed: 20030375
Curr Oncol Rep. 2020 Feb 1;22(2):13
pubmed: 32008109
Blood. 2009 Sep 24;114(13):2721-9
pubmed: 19633198
Pharmacogenomics. 2009 Oct;10(10):1657-74
pubmed: 19842938
Microb Biotechnol. 2017 Jul;10(4):910-925
pubmed: 28557379
Oncotarget. 2018 Apr 13;9(28):19929-19944
pubmed: 29731994
Clin Cancer Res. 2001 Oct;7(10):3251-7
pubmed: 11595721
Ann Oncol. 1998 Sep;9(9):981-7
pubmed: 9818072
Adv Drug Deliv Rev. 2016 Oct 1;105(Pt A):96-106
pubmed: 27094795
Blood. 2003 Aug 15;102(4):1458-65
pubmed: 12714494
Med Res Rev. 2018 Jul;38(4):1255-1294
pubmed: 29064108
Anticancer Drugs. 2006 Jan;17(1):25-31
pubmed: 16317287
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6780-4
pubmed: 10841573
Cancer Res. 1995 Aug 1;55(15):3352-6
pubmed: 7614470
Anticancer Agents Med Chem. 2009 Feb;9(2):122-37
pubmed: 19199861
J Nat Prod. 2002 Mar;65(3):295-8
pubmed: 11908968
Haematologica. 2011 May;96(5):687-95
pubmed: 21330323
Mar Drugs. 2012 May;10(5):963-86
pubmed: 22822350
Nat Prod Rep. 2014 Aug;31(8):999-1025
pubmed: 24871201
Nat Prod Res. 2016 Dec;30(24):2783-2790
pubmed: 26946937
Mol Cancer Ther. 2005 Jul;4(7):1086-95
pubmed: 16020666
Cancer Chemother Pharmacol. 2005 Oct;56(4):436-46
pubmed: 15902462
Br J Cancer. 2017 Jan;116(3):335-343
pubmed: 28072764
Blood. 2009 Apr 16;113(16):3781-91
pubmed: 19020308
Oncologist. 2008 Jun;13(6):709-14
pubmed: 18586926
Clin Cancer Res. 2017 Feb 15;23(4):992-1000
pubmed: 27573171
Blood. 2017 Dec 21;130(25):2709-2717
pubmed: 28974506
Cancer Res. 2001 Feb 1;61(3):1013-21
pubmed: 11221827
Mol Cancer Ther. 2018 Nov;17(11):2412-2426
pubmed: 30126944
N Engl J Med. 2018 Jan 25;378(4):331-344
pubmed: 29224502
Nat Prod Rep. 2000 Jun;17(3):215-34
pubmed: 10888010
Clin Cancer Res. 2006 Oct 1;12(19):5809-16
pubmed: 17020988
Bioorg Med Chem. 2000 Aug;8(8):1841-60
pubmed: 11003129
Cancer Res. 1994 Jan 1;54(1):165-8
pubmed: 8261437
J Nat Prod. 1981 Jul-Aug;44(4):482-5
pubmed: 7288444
Cancer Chemother Pharmacol. 2020 Feb;85(2):461-468
pubmed: 31811421
Oncogene. 2002 Oct 24;21(49):7533-44
pubmed: 12386816
Future Oncol. 2019 Jan;15(2):109-120
pubmed: 30111169
Mar Drugs. 2010 Mar 25;8(4):835-80
pubmed: 20479958
Science. 2017 Oct 13;358(6360):218-223
pubmed: 29026042
Adv Food Nutr Res. 2011;64:213-24
pubmed: 22054949
Mar Drugs. 2019 Jan 07;17(1):
pubmed: 30621045
Med Res Rev. 2000 Jan;20(1):1-27
pubmed: 10608919
Blood Adv. 2019 Feb 26;3(4):633-643
pubmed: 30804017
Cancer Cell. 2013 Feb 11;23(2):249-62
pubmed: 23410977
Clin Cancer Res. 2001 Jan;7(1):38-42
pubmed: 11205915
Clin Cancer Res. 2000 Mar;6(3):825-8
pubmed: 10741703
Cancer Res. 2005 Apr 1;65(7):2964-71
pubmed: 15805300
Clin Cancer Res. 1998 Mar;4(3):611-8
pubmed: 9533528
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5929-35
pubmed: 14676117
Cancer Chemother Pharmacol. 2013 May;71(5):1247-54
pubmed: 23455428
Mol Cancer Ther. 2016 Oct;15(10):2399-2412
pubmed: 27630271
Cancer Chemother Pharmacol. 2016 Apr;77(4):663-71
pubmed: 26666647
Drugs. 2017 Jul;77(11):1251-1259
pubmed: 28612232
Sci Rep. 2016 Oct 07;6:35100
pubmed: 27713531
Eur J Cancer. 2001 Jan;37(1):97-105
pubmed: 11165136
J Med Chem. 2014 Dec 26;57(24):10527-43
pubmed: 25431858
J Neurooncol. 2007 Jan;81(2):201-8
pubmed: 16941075
Nature. 1970 Aug 29;227(5261):962-3
pubmed: 4393654
Mar Drugs. 2015 May 13;13(5):2924-54
pubmed: 25984990
mBio. 2018 May 22;9(3):
pubmed: 29789364
Mol Cancer Ther. 2020 Jan;19(1):157-167
pubmed: 31597712
Microb Biotechnol. 2010 Sep;3(5):544-63
pubmed: 21255352
Br J Haematol. 2016 Feb;172(4):625-8
pubmed: 26033438
Mar Biotechnol (NY). 2003 Jan-Feb;5(1):13-9
pubmed: 12925914
J Clin Oncol. 2012 Jun 20;30(18):2190-6
pubmed: 22614995
J Nat Prod. 2001 Jul;64(7):907-10
pubmed: 11473421
Am J Clin Oncol. 2000 Jun;23(3):273-7
pubmed: 10857892
Int J Mol Sci. 2020 Jul 31;21(15):
pubmed: 32752132
Br J Cancer. 2005 Dec 12;93(12):1388-94
pubmed: 16333246
Haematologica. 2012 May;97(5):771-9
pubmed: 22180432
Nat Prod Rep. 2019 Mar 20;36(3):458-475
pubmed: 30191940
Bioconjug Chem. 2006 Jan-Feb;17(1):114-24
pubmed: 16417259
J Nat Prod. 2004 Feb;67(2):129-35
pubmed: 14987046
Clin J Pain. 2002 Jul-Aug;18(4 Suppl):S3-13
pubmed: 12479250
Nat Prod Rep. 2002 Aug;19(4):413-53
pubmed: 12195811
Biomed Res Int. 2013;2013:604787
pubmed: 24078922
Exp Hematol Oncol. 2012 Apr 05;1(1):4
pubmed: 23210930
Appl Environ Microbiol. 2001 Oct;67(10):4531-7
pubmed: 11571152
Haematologica. 2017 Jan;102(1):168-175
pubmed: 27540138
Clin Cancer Res. 1998 May;4(5):1305-14
pubmed: 9607591
Nat Prod Rep. 2009 Mar;26(3):322-37
pubmed: 19240944
Int J Cancer. 2013 Nov;133(9):2024-33
pubmed: 23588839
Cancer Res. 1982 Jul;42(7):2587-91
pubmed: 7083151
Angew Chem Int Ed Engl. 2010 Dec 3;49(49):9346-67
pubmed: 20927786
Leukemia. 2015 Jul;29(7):1578-86
pubmed: 25708834
Microbes Environ. 2013;28(1):13-24
pubmed: 23363620
C R Biol. 2011 May;334(5-6):435-40
pubmed: 21640952
ACS Chem Biol. 2011 Nov 18;6(11):1244-56
pubmed: 21875091
Br J Pharmacol. 2010 Nov;161(5):1099-110
pubmed: 20977459
Int Immunopharmacol. 2009 Mar;9(3):324-9
pubmed: 19159698
Clin Cancer Res. 1998 May;4(5):1337-43
pubmed: 9607595
J Physiol. 2006 Sep 15;575(Pt 3):845-54
pubmed: 16825310
Nat Prod Rep. 2008 Jun;25(3):475-516
pubmed: 18497896
Lancet Oncol. 2020 May;21(5):645-654
pubmed: 32224306
Mol Cancer Ther. 2018 Apr;17(4):795-805
pubmed: 29483208
Mar Drugs. 2020 Jan 09;18(1):
pubmed: 31936539
J Med Chem. 1991 Nov;34(11):3339-40
pubmed: 1956053
Sci Rep. 2015 Feb 25;5:8608
pubmed: 25712739
Mol Pharmacol. 1982 Mar;21(2):474-7
pubmed: 7048062
Food Chem Toxicol. 2014 Feb;64:344-52
pubmed: 24333868
Lancet. 2011 Mar 12;377(9769):914-23
pubmed: 21376385
Pharmaceuticals (Basel). 2020 Sep 14;13(9):
pubmed: 32937862
Br J Pharmacol. 2020 Jan;177(1):3-27
pubmed: 31621891
J Clin Oncol. 2016 Mar 10;34(8):786-93
pubmed: 26371143
Mar Drugs. 2014 Jan 27;12(2):719-33
pubmed: 24473171
Ann Hematol. 2019 Sep;98(9):2139-2150
pubmed: 31240472
Mar Drugs. 2015 Sep 24;13(10):6099-116
pubmed: 26404322
JCI Insight. 2019 Nov 1;4(21):
pubmed: 31600169
Oecologia. 2004 Mar;139(1):131-9
pubmed: 14747940
Chem Rev. 2009 Jul;109(7):3012-43
pubmed: 19422222
Invest New Drugs. 1999;17(2):179-82
pubmed: 10638489
Lancet. 2016 Apr 16;387(10028):1629-37
pubmed: 26874885
Nat Rev Drug Discov. 2009 Jan;8(1):69-85
pubmed: 19096380
Br J Cancer. 1993 Aug;68(2):418-24
pubmed: 8347500
Oncologist. 2011;16(1):97-104
pubmed: 21212432
J Nat Prod. 2017 Sep 22;80(9):2484-2491
pubmed: 28885014
Br J Haematol. 2019 Mar;184(6):1022-1025
pubmed: 29611184
Mol Pharmacol. 1984 Jul;26(1):128-34
pubmed: 6431261
Angew Chem Int Ed Engl. 2003 Jan 20;42(3):355-7
pubmed: 12548698
Eur J Med Chem. 2020 Dec 15;208:112829
pubmed: 33002736
Nat Biotechnol. 2003 Jul;21(7):778-84
pubmed: 12778055
Toxicol Lett. 2020 May 15;324:30-37
pubmed: 31877330
J Biol Chem. 1990 Sep 25;265(27):16617-25
pubmed: 1697861
J Clin Oncol. 2012 Jun 20;30(18):2183-9
pubmed: 22454421
Lancet Oncol. 2019 Jul;20(7):998-1010
pubmed: 31101489
Chem Asian J. 2010 Apr 1;5(4):704-54
pubmed: 20354984
Lancet Oncol. 2020 Feb;21(2):207-221
pubmed: 31859245
Am J Med. 1998 Mar 30;104(3A):2S-8S; discussion 21S-22S
pubmed: 9572314
Biosci Biotechnol Biochem. 1999 Jun;63(6):1130-3
pubmed: 10427703
Clin Cancer Res. 2012 Mar 15;18(6):1496-505
pubmed: 22282463
Oncotarget. 2016 Apr 5;7(14):18763-73
pubmed: 26936995
J Antibiot (Tokyo). 1977 Apr;30(4):275-82
pubmed: 863788
Cancer Res. 2016 May 15;76(10):3003-13
pubmed: 27013195
Eur J Cancer Clin Oncol. 1988 Nov;24(11):1699-706
pubmed: 3208814
Microb Biotechnol. 2019 Jan;12(1):55-57
pubmed: 30565871
Cell Physiol Biochem. 2018;49(5):1970-1986
pubmed: 30235439
J Nat Prod. 2009 Mar 27;72(3):540-53
pubmed: 19245259
Appl Environ Microbiol. 2002 Oct;68(10):5005-11
pubmed: 12324350
Br J Cancer. 2017 Aug 22;117(5):628-638
pubmed: 28683469
Br J Cancer. 1996 Apr;73(8):875-83
pubmed: 8611420
Mar Drugs. 2019 May 31;17(6):
pubmed: 31159276
Proc Natl Acad Sci U S A. 1986 Mar;83(5):1334-8
pubmed: 3456591
J Nat Prod. 2013 May 24;76(5):983-7
pubmed: 23701598
Cell Rep. 2019 Sep 24;28(13):3367-3380.e8
pubmed: 31553907
Chem Biol. 2012 Jan 27;19(1):85-98
pubmed: 22284357
Invest New Drugs. 2005 Oct;23(5):489-93
pubmed: 16133801
J Clin Oncol. 2020 Jan 10;38(2):155-165
pubmed: 31693429
J Genet Eng Biotechnol. 2018 Jun;16(1):1-8
pubmed: 30647697
Ann N Y Acad Sci. 2000;922:1-10
pubmed: 11193884
Nat Med. 2001 Aug;7(8):961-6
pubmed: 11479630
Clin Cancer Res. 2017 Nov 1;23(21):6384-6389
pubmed: 28242632
Br J Cancer. 2003 Oct 20;89(8):1418-22
pubmed: 14562010
Curr Opin Biotechnol. 2010 Dec;21(6):777-9
pubmed: 21055916
Indian J Anaesth. 2016 Nov;60(11):861-862
pubmed: 27942064
Cancer Cell Int. 2020 May 7;20:154
pubmed: 32410882
Mol Cancer Ther. 2005 Feb;4(2):333-42
pubmed: 15713904
Mar Drugs. 2014 May 02;12(5):2539-89
pubmed: 24798925
Invest New Drugs. 2005 Jun;23(3):257-61
pubmed: 15868383
Biomol Ther (Seoul). 2016 Nov 1;24(6):561-571
pubmed: 27795450
J Neurooncol. 2002 May;57(3):231-9
pubmed: 12125986
Clin Exp Metastasis. 1998 Aug;16(6):541-50
pubmed: 9872601
Clin Cancer Res. 2000 Nov;6(11):4205-8
pubmed: 11106233